期刊文献+

B-型钠尿肽在慢性充血性心力衰竭诊疗中的临床应用 被引量:8

B type natriuretic peptide apply for dignosis and treatment in patients with congestive heart failure
下载PDF
导出
摘要 目的研究慢性充血性心力衰竭患者血浆B-型钠尿肽水平的变化及其与心功能状态、心脏结构的关系,探讨其用于慢性充血性心力衰竭诊断价值。方法按美国NYHA心功能分级标准,随机抽取心功能Ⅱ级、Ⅲ级、Ⅳ级内科住院患者共96例,先测定血浆BNP的含量,待慢性充血性心力衰竭患者经治疗症状缓解后同法测上述指标,并进行数据分析;心脏彩色多普勒超声诊断仪测量左室结构和功能。结果不同心功能分级患者的血浆BNP水平差异具统计学意义,经抗心衰治疗后,患者心衰症状缓解,BNP含量下降,BNP的变化有统计学意义。血浆BNP水平和LVEF呈负相关(γ=-0.37,P<0.05),与左室舒张末期内径(LVEDD)呈正相关(γ=0.36,P<0.05)。结论血浆BNP水平和心脏结构相关,是慢性充血性心力衰竭诊断、治疗疗效评价的敏感指标。 Objective This study was performed to explore the correlation among plasma levels of B type natriuretic peptides(BNP) and the left ventricular function and structure in patients with chronic heart failure (CHF), and to evaluate the value of plasma levels of B type natriuretic petides in the CHF diagnosis. Methods According to NYHA Class ,96 patients on random were selected. They were assigned to groups , NYHA Ⅱ, NYHA Ⅲ ,and NYHA Ⅳ.BNP plasma levels were measured just before treatement and after treatement in improvement of patients's symptom. Datas was analyzed among patients with NYHA. Doppler echoear-diography was perfoimed to measure left ventricular function and structure. Results Significant differences existed BNP level among NYHA Class.BNP level was significantly lower after treatment.Improvement of patients's symptom was positively correlated to the change of BNP level (P〈0.05). plasma level of BNP had a negative correlation with LVEF(T=-0.37,P〈0.05)and BNP plasma level had a positive correlation with left ventricular end-diastolic diameter (T=0.36,P〈0.05). Conclusion BNP level had close relationship with left ventricular structure. Measuring of plasma BNP level might be a sensitive biomarker in diagnosis and treatment of congestive heart failure.
出处 《安徽医学》 2009年第4期430-432,共3页 Anhui Medical Journal
关键词 充血性心力衰竭 B型钠尿肽 临床应用 Congestive heart failure B type natriuretic peptide Clinical application
  • 相关文献

参考文献10

  • 1杨起鹏.单硝酸异山梨酯治疗慢性充血性心力衰竭的临床观察[J].实用医学杂志,2007,23(13):2081-2082. 被引量:24
  • 2Tamura N, Ogawa Y, Yasoda A, et al. Two cardiac natriuretic peptide genes (atrial natriuretic peptide and brain natriuretic peptide) are organized in tandem in the mouse and human genomes. J Mol Cell Cardiol,1996,28:1 811.
  • 3Cowie MR, Mendez GF. BNP and congestive heart failure. Prog Cardiovasc Dis, 2002,44(4):293.
  • 4Shapiro BP, Chen HH,Burnett JC , et al. Use of plasma brain natriureticpep tide concentration to aid in the diagnosis of heart failure. Mayo Clin Proc, 2003, 7(8): 4 812-4 816.
  • 5Krishnaswamy P,Lubien E,Clopton P, et al.Utility of B-natriureic peptide levels in identifying patients with left ventricular systolic or diastolic dysfunction.Am J Med,2001,111 274-279.
  • 6羊镇宇,王如兴,李肖蓉,刘志华.B型利钠肽测定对充血性心力衰竭患者预后评估的研究[J].中国心血管杂志,2005,10(3):201-203. 被引量:5
  • 7Catuzzo B,Ciancamerla F,Bobbio M,et al. In patients with severesystolic dysfunction,only brain natriuretic peptide is related todiastolic restrictive patern . J Card Fail ,2003,9 (4): 303- 310.
  • 8Mair J,Lercher AH,Puschendort B.The impact of cardiac natriuretic peptide determination on the diagnosis and management of heart failure.Clin Chem Lab Med,2001,3(9):5 712-5 718.
  • 9Cheng VL , Krishnaswamy P , Kazanegra R , et al. A rapid bedside test for B-type natriuretic peptide predicts treatment outcomes in patients admitted with decompensated heart failure. J Clin Cardial ,2001,3(7):386-391.
  • 10Kawai K,Hata K,Takaoka H,et al.Plasma brain natriuretic peptide as a novel therapeutic indicatror in idiopathic dilated cardiomyopathy during beta-blocker therapy:a potential of hormone-gurided treatment.Am Heart J,2001,14l(6):925-932.

二级参考文献13

  • 1高雷山.单硝酸异山梨酯联合硝苯地平治疗慢性肺源性心脏病心力衰竭疗效观察[J].中国呼吸与危重监护杂志,2006,5(3):204-204. 被引量:3
  • 2Wilkins MR, Redondo J, Brown LA. The natriuretic peptide family[J]. Lancet, 1997,349: 1307-1310.
  • 3Luchner A, Stevens TL, 13orgeson DD, et al. Different atrial and ventricular expression of myocardial BNP during evolution of heart failure [J]. Am J Physiol. 1998,274:H1684-1689.
  • 4Mair J, Lercher All, Puschendort B. The impact of cardiac natriuretic peptide determination on the diagncxsis and management of heart failure [J]. Clin Chem Lab Med,2001,39 : 571-588.
  • 5Tsutamoto T, Wada A, Maeda K, et al. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure prognostic role of plasm abrain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction [J].Circulation, 1997,96: 509-516.
  • 6Maeda K, Takayoshi T, Wada A, et al. Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end diastolic procure in patients with symptomatic left ventricular dysfunction [J]. Am Heart J,1998, 135:825-823.
  • 7Mair J, Lercher AH, Puschendort B. The impact of cardiac natriuretic peptide determination on the diagnosis and management of heart failure [J ]. Clin Chem Lab Med,2001,39 : 571-588.
  • 8Cheng VL, Krishnekswamy P, Kazanegra R, et al. A rapid bedside test for B-type natriuretic peptide predicts treatment outcomes in patients admitted with decompensated heart failure[J ]. J Am Coll Cardiol, 2001,37 : 386-391.
  • 9Tsutamoto T, Wada A, Maeda K, et al. Plasma brain natriuretic peptide level as a biochemical marker of morbidity and mortality in patients with asymptomatic left ventricular dysfunction-comparison with angiotensin Ⅱ and endothelin-1[J]. Eur Heart J, 1999, 20: 1799-1807.
  • 10王海昌,贾国良,译.心脏病学[M].2版.西安:第四军医大学出版社,2003:886.

共引文献27

同被引文献99

引证文献8

二级引证文献41

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部